We show in this study that PTEN regulates p53 protein levels and transcriptional activity through both phosphatasedependent and -independent mechanisms. The onset of tumor development in p53
Tumor suppressor genes are conceptually regarded as autonomous anti-cancer units. Along this tenet, only their homozygous loss would lead to cancer pathogenesis (Knudson, 1971) . At the cellular level, however, autonomy appears to be a remote concept since protein function and gene expression are well regulated through cooperating and antagonizing networks. Therefore, linking the regulatory mechanisms between tumor suppressors is key to understanding, predicting, and interfering with tumorigenesis. Given that previous work has demonstrated several layers of indirect crosstalk between the two most highly mutated tumor suppressors, p53 and PTEN, it would have certainly been tempting to speculate that PTEN also directly cooperates with p53 in tumor suppression. Mechanistically however, the role of PTEN in tumor suppression has been attributed to the cytoplasm while the site of action of p53 is definitely ascribed to the nucleus, thus rendering it problematic to envision how this would occur. According to a study published in this issue of Cancer Cell (Freeman et al., 2003) , a direct functional crosstalk between PTEN and p53 does indeed exist, adding a novel twist to the emerging picture of the PTEN-p53 tumor suppressor network.
The p53 tumor suppressor acts as a transcription factor capable of regulating the expression of target genes critical for growth inhibition, cell senescence, and induction of apoptosis in response to DNA damage and oncogenic transformation (Sharpless and DePinho, 2002) . Cells are therefore extremely sensitive to p53 levels and transcriptional activation. In the absence of stress, levels of p53 in normal cells are maintained low mostly through its constant proteasome-dependent degradation mediated by the mdm2 protein that acts as a p53 ubiquitinligase. A number of p53 posttranslational modifications that are subjected to a dynamic and tight regulation including phosphorylation, acetylation, and sumoylation lead to its stabilization and transcriptional activation upon cellular stress. The extraordinary multilayered complexity of the p53 regulatory network and its central importance in tumor suppression make it an ideal molecular platform on which other tumor-suppressive pathways could impinge.
PTEN (for phosphatase and tensin homolog deleted on chromosome 10) mutations and partial or complete loss have been frequently reported in tumors of various histological origins. PTEN is also found mutated in three related human autosomal dominant disorders characterized by developmental defects and high tumor susceptibility (Di Cristofano and Pandolfi, 2000) .
The PTEN gene encodes a dual specificity phosphatase, which to some surprise, however, has been shown to primarily dephosphorylate the plasma membrane lipid phosphatidyl-inositol-3-phosphate (PIP3) whereas examples of protein targets have remained rare. Conversion of PIP3 to PIP2, however, enables PTEN to effectively antagonize the PI3 kinase pathway, resulting in inactivation of the many PH domain-containing downstream protein kinases, most notably Akt and PDK1 (Cantley, 2002) , which in turn act on a variety of proteins to stimulate cell survival, proliferation, growth, and migration.
In the mouse, complete Pten inactivation is embryonic lethal while Pten heterozygous mice co-develop, after a latency period, multiple tumors of various histological origins in complete agreement with an important and pleiotropic tumor suppressive role (Di Cristofano and Pandolfi, 2000) . In Pten heterozygous mutants that have also lost one or both copies of the p27 KIP1 gene, encoding a cell cycle inhibitor whose loss does not cause an overt cancer phenotype, Pten-specific tumors are markedly accelerated (Di Cristofano et al., 2001) . Most notably, these tumors retain Pten expression, indicating that its tumor-suppressive function might be dose dependent, and Pten thus haploinsufficient in certain tissues in combination with loss of another tumor suppressor. These findings underscored the importance of establishing the regulatory mechanisms governing PTEN protein levels and activity as their tight regulation may be critical for tumor suppression.
The first report to link PTEN and p53 on a molecular level showed direct binding of p53 to a site in the PTEN promoter (Stambolic et al., 2001 ). On top of p53-independent basal expression, DNAdamaging events such as γ irradiation resulted in a p53-dependent increase of PTEN mRNA in several cell lines ( Figure  1A , pathway 2). Moreover, in Pten null mouse embryonic fibroblasts (MEFs), p53-mediated apoptosis was impaired, underscoring the potential importance of Pten transactivation for this process. Altogether, this report positioned p53 upstream of PTEN in the regulation of its expression level. However, it soon became apparent that PTEN could also regulate p53 function through its ability to antagonize PI3 kinase since Akt phosphorylation consensus sites were identified in mdm2, one of the major negative regulators of p53 (Mayo and Donner, 2001; Zhou et al., 2001) . Upon phosphorylation of these sites, mdm2 translocated into the cell nucleus to ubiquitinate p53, resulting in its nuclear export and degradation. Since PTEN phosphatase activity is the major antagonist of Akt, it was therefore tempting to speculate that PTEN would prevent this p53 degradation pathway by keeping Akt inactive and that PTEN would therefore be an essential component of the p53 response upon DNA damage ( Figure 1A , pathway 1). Indeed, the effect of PTEN on p53-mediated transcription was also soon reported . PTEN, but not a phosphatase-dead mutant, was able to produce a moderate increase of p53-mediated transcription even in the presence of mdm2, indicating that PTEN by antagonizing PI3 kinase can indirectly protect p53 from the degradation pathway. Importantly, the above findings suggested that PI3 kinase inhibitors such as Wortmannin could sensitize refractory tumors with wt p53 to treatment with p53-inducing drugs such as etoposide by mimicking PTEN activity and thus increasing p53 stability (see Figure 1B) .
In a study appearing in this issue of Cancer Cell (Freeman et al., 2003) , the PTEN-p53 crosstalk is taken a step further by identifying a p53 binding domain in PTEN. By performing GST-pulldown experiments with p53 deletion mutants, the C terminus of p53 was found to bind PTEN. These in vitro binding studies could be confirmed by a series of coimmunoprecipitations in both human cell lines and in cells derived from a Pten conditional mouse knockout model. Intriguingly, on PTEN, the p53 binding activity was mapped to the C2 domain, which so far had only been implicated in stabilizing and properly positioning the catalytic phosphatase domain of PTEN at the plasma membrane (Georgescu et al., 2000; Lee et al., 1999) . This finding led the authors to ask whether PTEN might regulate p53 activity independently of its enzymatic activity. The results indicate that phosphatase-dead mutants P R E V I E W S Figure 1 . Functional crosstalk between PTEN and p53 and its therapeutic implications A: PTEN and p53 interact on three levels. 1: The PTEN phosphatase inhibits activation of mdm2 by keeping Akt inactive. Akt, when activated through the PI3 kinase pathway, can phosphorylate cytoplasmic mdm2, resulting in its nuclear import. Nuclear mdm2 ubiquitinates p53 and targets it for proteasomal degradation in the cytoplasm.
2: DNA damage results in a sharp increase of p53 protein which, in turn, can enhance PTEN transcription by binding to the PTEN promoter leading to a positive feedback loop that protects p53 from degradation.
3: Pten binds to p53 resulting in increased p53 half-life. This interaction also stimulates p53-mediated transcription, although it is still unclear whether PTEN participates in a p53-DNA complex. Cytoplasmic PTEN may also antagonize p53 degradation by cytoplasmic proteasomes.
Active or inactive forms of enzymes are denoted by an "a" or "i" superscript, respectively.
B:
Tumor cells can be resensitized to DNA damage-inducing agents.
Tumor cells can be incapable of a p53 response in spite of having the functional protein because loss of, e.g., PTEN function results in increased PI3 kinase activity. Thus, combination of DNA damage-inducing agents with PI3 kinase inhibitors can restore drug sensitivity.
of PTEN are capable of stabilizing p53 as well. In half-life experiments, catalytically inactive PTEN could even protect p53 from mdm2-independent degradation, indicating that it can counteract additional mechanisms aimed at degrading p53. In this respect, it could be speculated that PTEN can also compete with proteasomal degradation of p53 in the cytoplasm ( Figure 1A , pathway 3). In human SAOS2 cells, it was furthermore observed that protection did not affect p53 mRNA levels, consistent with degradation occurring at the protein level. Next, the authors tested whether the interaction with PTEN might separately enhance p53-mediated transcription. In transcription transactivation assays adding back PTEN into Pten null MEFs, an increase in p53-mediated transcription could be observed in agreement with the previous findings by Mayo et al. However, in conflict with that report, add back of a phosphatase-dead PTEN mutant or the PTEN C2 domain only still resulted in some stimulation of p53 transactivation, consistent with a role for direct interaction in p53 stabilization. Given the multiple levels of crosstalk, it is not yet clear whether PTEN activates p53-mediated transcription per se in addition to protecting it from degradation. Also surprisingly, the study could be carried out in MEF cells that unexpectedly expressed high levels of p53, while usually such p53 levels have to be induced by DNA-damaging agents. Results obtained by electrophoretic mobility shift analysis left the question of a PTEN-p53 complex on DNA still open, while chromatin immunoprecipitation experiments using a p53 antibody and p21-specific primers confirmed the notion that transfection of PTEN independently of its enzymatic activity may result in an increase of p53 levels, hence potentiating its function. To assess the importance of Pten-p53 interactions in vivo, the authors made use of a compound mutant mouse model by crossing Pten and p53 knockout mutant mice. They found that in a p53 heterozygous background, the status of Pten was crucial since loss of just one allele of Pten dramatically accelerated tumor onset to the rate observed in p53 null mice. Although mutations of the remaining p53 and Pten alleles were not formally excluded, these preliminary results are in agreement with the author's observations in murine cell lines. In summary, compelling experimental evidence unraveling an intimate functional crosstalk between PTEN and p53 has been accrued in the past two years. These findings are in agreement with a recent observation made in human breast cancers, demonstrating that PTEN and p53 somatic mutations are mutually exclusive and do not occur in the same compartment (stroma versus epithelium) or in the same sample (Kurose et al., 2002) .
The study by Wu and colleagues raises many important questions. It is not presently clear how much a direct interaction with PTEN contributes to p53 stabilization, nor is it known how PTEN binding would lead to p53 stabilization. It would also be interesting to determine whether p53 modifications such as phosphorylation or ubiquitination affect it or if, in turn, PTEN binding regulates these posttranslational modifications. If PTEN interacts with p53 in the cytoplasm ( Figure 1A , pathway 3) and whether this regulates p53 nuclear import need also to be assessed. This is of particular relevance in view of the recent identification of proteins such as PARC that actively anchor p53 in the cytoplasm in the absence of cellular stress (Nikolaev et al., 2003) . It also remains to be determined to what extent p53-mediated apoptosis depends on a direct PTEN-p53 interaction. To this end, it will be important to study whether cancer-associated mutations of PTEN or p53 specifically interfere with their interaction, which would firmly establish the relevance of the novel finding to human disease. al., 1999) . Many cancer-related mutations have been mapped within the conserved catalytic domain of PTEN, suggesting that PTEN (phosphatase and tensin homolog deleted on chromothe phosphatase activity of PTEN is required for its tumor supsome 10) tumor suppressor gene was the first phosphatase pressor function. In addition to its phosphatase domain, PTEN identified to be frequently mutated/deleted somatically in varialso contains a putative C2 regulatory domain, a PIP2 binding ous human cancers Steck et al., 1997) . motif, two PEST homology regions, and a consensus PDZ bindIn addition, germline mutations in the PTEN gene have been ing site. The functions of these structural domains include reguassociated with Cowden syndrome and related diseases in lating the phosphatase activity and controlling the stability or which patients develop hyperplastic lesions (harmatomas) in subcellular localization of PTEN (Maehama et al., 2001) . Disrupmultiple organs with increased risks of malignant transformation tion of the murine Pten locus further supports the importance (Liaw et al., 1997; Marsh et al., 1998; Nelen et al., 1997) . PTEN of PTEN as a bona fide tumor suppressor (Di Cristofano et al., contains a sequence motif that is highly conserved in the mem-1998; Podsypanina et al., 1999; Suzuki et al., 1998) . Homozybers of the protein tyrosine phosphatase family. PTEN has been gous deletion of Pten results in early embryonic lethality. Pten shown to possess phosphatase activity on phosphotyrosyl and heterozygous mice develop hyperplastic/neoplastic changes in multiple organs as early as 4 weeks, with a bias toward incidence phosphothreonyl-containing substrates Myers and Tonks, 1997) in vitro and on phosphatidylinositol (3, 4, 5) in lymphoid, endometrial, mammary, gastrointestinal, and adrenal gland tissues (Podsypanina et al., 1999; Suzuki et al., 1998) . trisphosphate, a product of phosphatidylinositol 3-kinase (PI3K), both in vitro and in vivo (Lee et al., 1999; Maehama and The major function of the tumor suppressor PTEN relies on its phosphatase activity and subsequent antagonism of the Dixon, 1998; Myers et al., 1998; Stambolic et al., 1998; 
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S I G N I F I C A N C E
It has been shown by many groups, including our own, that the major function of the PTEN tumor suppressor relies on its phosphatase activity by antagonizing the PI3K/AKT pathway. This study provides evidence that PTEN can modulate p53 function independently of its phosphatase activity, and that a physical interaction between PTEN and p53 is important for this modulation in vivo. We also provide in vivo evidence for PTEN's function inside of the nucleus. Consequently, our study provides a novel mechanism by which PTEN regulates p53 levels and activities, and possibly provides an avenue for targeted therapy for cancers caused by PTEN or p53 loss. (Franke et al., 1997; Stambolic et al., 1998; Sun et al., 1999; Wu et al., 1998) . As a PTEN and p53: A genetic study We have generated a Pten-deficient mouse line by homologous serine/threonine protein kinase, AKT functions by phosphorylating key intermediate signaling molecules, leading to increased recombination via embryonic stem cells (ES cells). Similar to previous reports, mice lacking PTEN died early during embryocell metabolism, cell growth, cell survival, and cell invasiveness-all hallmarks of cancer (for review, see Downward, 1998;  genesis, and mice with heterozygous Pten deletion developed tumors in various tissues ( Figure 1A ). However, the conse- Hanahan and Weinberg, 2000; Hill and Hemmings, 2002) . Genetic studies also indicate that AKT plays an essential role in quences of Pten inactivation on a 129/Balb/c genetic background are quite different from what was reported on a 129/ PTEN-controlled signal transduction and tumorigenesis (Stiles et al., 2002; Stocker et al., 2002) .
C57 background (R. Lesche et al., submitted) . In particular, most of the heterozygous mice are tumor free for the first six Recent studies suggest that there is a tight link between PTEN and p53, another major tumor suppressor. Both PTEN months of their postnatal life: 10% of Pten ϩ/Ϫ animals developed focal lymphoid hyperplasia in the thymus and enlarged lymph and p53 regulate cell proliferation and cell death (for review, see Bargonetti and Manfredi, 2002; Yamada and Araki, 2001) .
nodes near the neck and axilla ( Figure 1A , left). Among aged animals (7-14 months), 25% of them developed lymphoid hyEven though PTEN and p53 are frequently mutated in both inherited and spontaneous tumors in humans, concomitant muperplasia/dysplasia ( Figure 1A , right) and 10% of those progressed to early lymphoblastic lymphoma of T cell origin, similar tations in both p53 and PTEN loci are not common (Kurose et al., 2002; Fujisawa et al., 2000; Kato et al., 2000; Koul et al., to previous reports (Podsypanina et al., 1999; Suzuki et al., 1998) . This prolonged latency in tumor development provided us 2002; Rasheed et al., 1997) . Several commonly used human PTEN null tumor cell lines, such as U87 MG, 786-O, MCF-7, with a unique opportunity to genetically evaluate the possible interaction between PTEN and p53. We generated mice heteroand LNCap, are wild-type for p53. These genetic observations suggest that loss of PTEN may reduce the selective pressure on zygous for both p53 and Pten (compound heterozygous,
) on the 129/Balb/c background and followed a tumors during cancer progression to lose p53. Mechanistically, several lines of evidence suggest that PTEN-controlled AKT cohort of compound heterozygous animals (n ϭ 33; male: female ϭ 14:19) for six months. Seven p53 ϩ/Ϫ ;Pten ϩ/Ϫ mice activation plays an essential role in modulating MDM2-dependent p53 degradation (for review, see Mayo and Donner, 2002;  died between 2-6 months of age. The rest of the animals were subjected to pathological analysis upon tumor development Zhou and Hung, 2002) . p53 is a short-lived protein and stabilization of p53 is crucial for its tumor suppressor function. The p53 from as early as 1 month of age. As shown in Figure 1B , the onset (left panel) and lymphoma (right panel) development in protein is maintained at low levels in normal cells by MDM2-mediated ubiquitination and subsequent proteolysis. AKT physithe p53 ϩ/Ϫ ;Pten ϩ/Ϫ mice are very similar to those of p53 Ϫ/Ϫ (n ϭ 23) mice, but differ significantly from mice heterozygous for p53 cally associates with MDM2 and phosphorylates MDM2 on serine residues, a key step involved in MDM2 nuclear translocation (Macleod and Jacks, 1999) and for Pten ( Figure 1A) . Similarly to what was reported in p53 Ϫ/Ϫ animals, p53
;Pten ϩ/Ϫ mice and MDM2-mediated p53 degradation (Mayo and Donner, 2001; Ogawara et al., 2002; Zhou et al., 2001) . Therefore, it is conceivdevelop lymphomas preferentially in the lymph nodes. As shown in Figure 1C , the enlarged lymph nodes are tightly packed with able that activation of AKT in PTEN-deficient cells may cause more rapid p53 degradation, which could contribute to tumoria dense population of homogeneous small lymphocytes with a few scattered germinal centers. Immunohistochemical staining genesis caused by PTEN loss. Furthermore, p53 can bind to the PTEN promoter region and activate PTEN transcriptionally using anti-CD3 antibody reveals nodules of uniform, atypical, immature T cells in the peri-follicular zones, suggesting early (Stambolic et al., 2001) , although there is a debate about the significance of such regulation (Sheng et al., 2002) .
lymphoblastic lymphoma of T cell origin. The majority of these samples have well-defined cortex and medullary with some To test the functional significance of the crosstalk between PTEN and p53 in vivo, we employed a genetic approach to highly vascularized areas. In 40% of cases, neoplastic lymphocytes are packed in the vessels and have infiltrated the surstudy tumorigenesis in Pten ϩ/Ϫ ;p53 ϩ/Ϫ compound heterozygous mice on a 129/Balb/c genetic background. We found that the rounding tissues (data not shown).
To ensure that the initiation of tumor development in onset of lymphoma development in p53 ϩ/Ϫ ;Pten ϩ/Ϫ mice is similar to that seen in p53 Ϫ/Ϫ animals. To further investigate the link p53
;Pten ϩ/Ϫ mice is not due to the loss of the second allele of either the Pten or p53 gene (loss of heterozygosity, LOH), between PTEN and p53, we demonstrated that p53 protein levels are dramatically reduced in Pten Ϫ/Ϫ cells and that PTEN immunohistochemical (IHC) analysis was performed on the tumors derived from the compound heterozygous (p53 ϩ/Ϫ ; stabilizes p53 by increasing its half-life. Furthermore, ectopic expression of PTEN phosphatase-dead mutants also leads to a Pten ϩ/Ϫ ) mice. Figure 2A shows that PTEN protein is present in these tumors (lower left) at levels similar to adjacent normal significant increase in p53 protein levels, and PTEN can stabilize p53, even in the absence of MDM2, suggesting that PTEN can tissues (lower right) and comparable to those of Pten ϩ/Ϫ mice (upper left). However, p53 is expressed at basal levels in most regulate p53 levels in a phosphatase-independent and MDM2-independent manner. Significantly, we observe that PTEN physiof the tissues and tumor samples and cannot be detected by conventional IHC analysis (data not shown). Thus, we concally associates with endogenous p53, and PTEN regulates the transcriptional activity of p53 by modulating its DNA binding.
ducted PCR and Western blot analysis. The second alleles of Pten and p53 are retained in the tumor samples ( Figure 2B ), Thus, PTEN-p53 may represent a self-reinforced circuit impor- and a substantial amount of p53 protein can also be detected PTEN modulates p53 protein stability To investigate whether PTEN indeed controls p53 function in in these tumors using an antibody that recognizes both WT and vivo, we first measured endogenous p53 mRNA and protein mutated form of p53 (Pab-240, Figure 2C , upper panel). To levels in isogenic Pten
, and Pten Ϫ/Ϫ ES cells. p53 ensure that WT p53 is present in the mutant sample, we conprotein levels are significantly reduced in Pten heterozygous ES ducted IP-Western blot analysis using an antibody that only cells and almost completely lost in Pten null ES cells (Figure reacts with WT p53 (Pab-246, Figure 2C , lower panel). It ap-3A, upper panel), while these ES cells do express similar levels pears, from this study, that WT p53 is present in the tumor of p53 mRNA ( Figure 3A , lower panel), suggesting that PTEN samples. These results lead to our conclusion that LOH is not modulates p53 at the posttranscriptional level. To confirm that required for the initiation of tumor development in these com-PTEN is capable of controlling p53 protein levels in vivo and to pound heterozygous mice. However, we cannot exclude (1) loss prove that this regulation is a common mechanism rather than of function mutations in either the p53 or Pten genes which a cell type-specific event, we measured p53 levels in brain cannot be detected by our assay systems; (2) localized or single tissues derived from Pten conditional knockout mice (Groszer cell-based allelic deletion or gene silencing events; and (3) that et al., 2001). Similarly to ES cell studies, p53 levels are reduced LOH is involved in or associated with tumor progression and in heterozygous animals and almost completely lost in Pten null brains ( Figure 3B ). To develop a system that is amenable to local invasion. biochemical analysis, we generated several isogenic mouse emof p53 in Pten loxp/loxp MEF cells was significantly longer than in Pten ⌬loxp/⌬loxp MEF (17 min versus 6 min, Figure 3D ), providing bryonic fibroblast (MEF) lines, which are wild-type for p53 but differ in their Pten status, first by immortalizing MEF cells from genetic evidence that PTEN controls endogenous p53 protein levels by modulating its protein stability. Interestingly, the halfPten conditional knockout mice (Lesche et al., 2002) org/cgi/content/full/3/2/117/DC1), suggesting that PTEN may both p53 and PTEN protein products, were treated transiently with Cre recombinase. Three independent clones, which carry a control p53 protein levels via both PI3 kinase/AKT-dependent and -independent mechanisms. homozygous Pten deletion ( Figure 3C , upper panel; Pten ⌬loxp/⌬loxp , functional equivalent to null mutant [⌬/⌬]) but are wild-type for p53, were generated and used for studies described below.
PTEN affects p53 protein stability: phosphatase and MDM2-independent mechanisms Similar to our analysis using ES cells and brain tissues, p53 protein levels, but not mRNA levels, were significantly reduced In order to determine whether reduced p53 stability in Pten null cells and tissues is due to a PTEN phosphatase-independent in Pten ⌬loxp/⌬loxp MEF cells ( Figure 3C ). MEFs are demonstrated by Northern blot analysis (lower panel). D: PTEN controls p53 half-life. Pten loxp/loxp and Pten ⌬loxp/⌬loxp MEF cells were cultured to 70% confluence before being transferred to serum free medium containing 50 g/ml cyclohexamide. Cells were directly lysed at the indicated time points and p53 proteins were detected by Western blot analysis. The half-life of p53 protein in the presence (first row) and absence (second row) of endogenous PTEN proteins were calculated using Quantity One (Bio-Rad).
protein levels (comparing lanes 2 and 3). Interestingly, two phosthe only mechanism by which PTEN can control p53. The fact that the PTEN phosphatase-dead mutants could regulate p53 phatase-dead mutants, PTEN-CS and PTEN-GR, as well as the PTEN-C2 domain alone, were also able to increase p53 protein levels ( Figures 4A and 4B ) suggests that PTEN can control p53 by multiple mechanisms, one of which does not require its levels, even though they did not affect AKT phosphorylation, a hallmark of PTEN's phosphatase activity ( Figure 4A , comparing phosphatase activity and thus may be MDM2 independent. To genetically prove that PTEN can control p53 in a MDM2-indelane 3 with lanes 4-6). We further tested the abilities of wild-type or PTEN-CS to modulate human p53 protein levels using p53 pendent manner, we took advantage of a p53
;Mdm2 Ϫ/Ϫ MEF cell line. As illustrated in Figure 4C , the expression of PTEN led null human osteosarcoma SAOS2 cells. Again, both the WT and PTEN-CS mutants led to a 5-to 6-fold increase in transfected to a near 7-fold increase in p53 protein levels in the absence of MDM2 ( Figure 4C, lanes 1 and 2) . Furthermore, PTEN expresp53 protein levels but not its mRNA levels ( Figure 4B ). These data suggest that (1) PTEN controls p53 protein levels in both sion could partially prevent p53 degradation caused by overexpression of MDM2 ( Figure 4C, lanes 3 and 4) . To further investihuman and murine cells; and (2) PTEN controls p53, at least in part, by a mechanism independent of its phosphatase activity.
gate the mechanism involved in MDM2-independent p53 stabilization by PTEN, we measured the half-life of p53 in The control of p53 protein levels is orchestrated by multiple factors with MDM2 being one of the major players. Thus, it is p53
;Mdm2 Ϫ/Ϫ MEF cells by transfecting p53 with and without PTEN. The half-life of p53 is significantly prolonged in the PTEN not surprising that increased AKT activity in Pten-deficient cells will lead to increased MDM2 phosphorylation and nuclear transco-transfected cells (15 hr; Figure 4D, ϩPTEN) , as compared to p53 alone (10 hr; Figure 4D , ϪPTEN). Again, PTEN-CS mutant location, resulting in p53 degradation. Similar to previous reports, MDM2 nuclear translocation is indeed increased in our had similar effect on p53 protein levels (see Supplemental Data at http://www.cancercell.org/cgi/content/full/3/2/117/DC1). Pten ⌬loxp/⌬loxp cells (see Supplemental Data on Cancer Cell website). However, the MDM2-dependent pathway is probably not How PTEN modulates p53 half-life in the absence of MDM2 is currently unknown and is worth further investigation. Taken tate each other in vivo in the Pten loxp/loxp cells while no PTEN/ together, the data indicate that PTEN can control p53 stability p53 complex formation could be detected in Pten ⌬loxp/⌬loxp cells by both phosphatase and MDM2-dependent and -independent ( Figure 5A , left panels). To determine whether PTEN, p53, and mechanisms.
MDM2 were in the same complex, we re-probed the blots with anti-MDM2 antibody and found that MDM2 is not in the PTEN/ p53 complex ( Figure 5A , upper right panel). Cell fractionation PTEN physically interacts with p53 and forms a PTEN/ studies indicate that the majority of the PTEN/p53 complex is p53 complex in the absence of MDM2 present in the nucleus ( Figure 5A , lower right panel Figure 5B ). Using various GST fusion proteins, we further mapped regions crucial for PTEN-p53 interaction to the careither an anti-PTEN or an anti-p53 antibody, respectively. Endogenous PTEN and p53 can reciprocally co-immunoprecipiboxy-terminal regulatory domain of p53 (R domain, amino acids Figure 6A ) and to the C2 domain of PTEN, which does were treated without or with leptomycin B (LMB), a nuclear not include any part of the PTEN phosphatase domain (Figexport inhibitor that can prevent p53 from degradation (Freedure 6B). man and Levine, 1998). LMB treatment rescued p53 protein in Pten ⌬loxp/⌬loxp (⌬/⌬) cells to a level comparable to the control cells ( Figure 7A , right panel), providing additional evidence that PTEN PTEN controls the transcriptional activity of p53 controls p53 protein levels by preventing p53 from degradation. To test the functional significance of the PTEN and p53 associaHowever, LMB treatment could not restore the transcriptional tion, we investigated whether PTEN could influence p53 tranactivity of p53 in Pten ⌬loxp/⌬loxp cells ( Figure 7A , left panel), indicatscriptional activity. p53 transcriptional activity is reduced by at ing that the physical interaction between PTEN and p53 is esleast 50% in Pten ⌬loxp/⌬loxp cells ( Figure 7A , left panel). To separate sential for maximizing p53Јs transcriptional activity. Overexpres-PTEN's role in enhancing p53 stability from increasing p53 transcriptional activity, Pten cells led to comparable increases in p53 transcriptional activity that lacks the PTEN binding domain, into p53-deficient SAOS2 cells ( Figure 7C ). These results suggest that the regions respon-( Figure 7B ), demonstrating that the reduced p53 transcriptional activity in Pten null cells is not due to mutations in the p53 gene.
363-393;
sible for the physical association between PTEN and p53 are crucial for PTEN's function in controlling p53 protein stability (FigInterestingly , expression of either PTEN-CS phosphatase-dead mutant or the C2 domain alone, which is important for p53 ure 4A) as well as its transcriptional activity ( Figures 7B and 7C ). Since PTEN controls G1-S transition and cell death through association, also leads to an increase, though to a lesser extent, of p53 transcriptional activity ( Figure 7B ). However, no further pathways overlapping with those controlled by p53, we are limited by the measurable biological effects that are solely deincrease in p53 transcriptional activity could be observed when we co-transfected WT PTEN with p53⌬C, an active form of p53 pendent on p53 function and not influenced by PTEN status. To demonstrate the biological consequence of Pten deletion trols p53 protein levels and transcriptional activity in vivo, and PTEN exerts its role through both phosphatase-dependent and on p53 functions, we measured the endogenous p21 mRNA levels in response to DNA damage. p21 is an immediate down--independent mechanisms. We also provide in vivo evidence for PTEN function inside of the nucleus, which has not been stream target gene for p53 transcriptional activity although p21 mRNA levels can be regulated by both p53-dependent and demonstrated before. Our initial studies rely on mice carrying mutations in the -independent mechanisms. Importantly, no literature has indicated that p21 transcriptional activation in response to UV treatendogenous gene encoding either p53 or Pten to avoid potential side effects caused by overpression of mutant proteins in a ment is controlled by the PTEN/PI3K/AKT pathway. As shown in Figure 7D , in response to UV irradiation, p21 mRNA levels tissue culture system. We hypothesized, based on the genetic data from p53 ϩ/Ϫ ;Pten ϩ/Ϫ heterozygous mice, that PTEN may are significantly increased in the WT MEFs; p53 ϩ/Ϫ cells are less responsive and p53 null cells are completely nonresponsive.
control p53 protein levels. This hypothesis was confirmed by measuring the endogenous p53 protein levels in isogenic Even though the basal mRNA level of p21 is not influenced by Pten status, its response to UV irradiation is impaired in Pten Pten ϩ/ϩ and Pten Ϫ/Ϫ ES cells, MEF cells, and brain tissues, as well as by measuring the half-life of p53 in the presence and null cells (Figure 7D, right) . Note the fold p21 mRNA increase in Pten null cells falls between p53 ϩ/Ϫ ;Pten ϩ/ϩ and p53 Ϫ/Ϫ ;Pten ϩ/ϩ absence of the endogenous PTEN proteins. These results provide genetic proof for PTEN's role in controlling p53 function. cells, which fits well with the endogenous p53 function. These results indicate that the endogenous p53 transcriptional activity Our study, together with those of others Mayo and Donner, 2001; Ogawara et al., 2002 ; Zhou et al., is indeed controlled by the PTEN tumor suppressor.
2001), may also help to explain why concomitant mutations in both p53 and PTEN loci are not common. PTEN plays an impor-PTEN controls p53 transcription activity by modulating its DNA binding tant role in regulating p53 protein levels and activity; loss of PTEN may decrease the selective pressure on tumors to lose Several proteins have been shown to interact with the p53 C-terminal domain and enhance p53 DNA binding by relieving p53 during cancer progression.
In an attempt to further delineate the functional domains the C-terminal inhibitory effect (Jayaraman et al., 1997a; Nie et al., 2000) . This prompted us to measure the possible effect of responsible for PTEN-mediated p53 stabilization, we discovered a critical role of phosphatase-independent activity of PTEN in PTEN on p53 DNA binding activity. Both WT PTEN and the PTEN-C2 (PTEN-C) fragment markedly enhanced the DNA bindregulating p53 protein levels and transcriptional activity. This conclusion is based on (1) reintroduction of PTEN phosphataseing activity of WT p53 ( Figure 8A , left panel, comparing lane 2 and lanes 3-6), similar to activation of p53 by c-Abl (lanes 14 and dead mutants as well as the PTEN-C2 region, which lack the phosphatase domain, into Pten ⌬loxp/⌬loxp cells partially rescues the 15). Consistent with our domain mapping studies, the PTEN-CT domain, which has weaker binding affinity to p53 (Figure 6B ), endogenous p53 protein levels ( Figure 4A ) and transcriptional activity ( Figure 7B ); (2) PTEN increases p53 protein levels and also has less effect on p53 DNA binding activity (lanes 7 and 8). Furthermore, PTEN had no effect on the DNA binding activity prolongs the half-life of p53 in the absence of MDM2 ( Figures  4C and 4D ). Since MDM2 is a key mediator for PI3K/AKT-conof the C-terminal truncated form of p53 (p53-⌬C), which lacks the PTEN association domain ( Figure 8A , right panel, comparing trolled p53 degradation, as suggested by previous studies, this result indicates that PTEN can control p53 half-life indepenlane 4 and lanes 5-7).
To show that PTEN can bind to p53 and enhance its DNA dently of PI3K/AKT/MDM2 via a currently unknown mechanism; (3) physical interaction of PTEN and p53 is crucial for maximum binding activity in vivo, we performed a chromatin immunoprecipitation analysis (ChIP) using the p21 promoter as a target.
p53 transcriptional activity (Figure 7 ), especially for its DNA binding activity (Figure 8 ). Both WT PTEN and PTEN-CS increase the binding activity of the endogenous p53 to the p21 promoter by 2.5-fold ( Figure  We by no means imply that the regulation of the PI3K/ AKT pathway is not an important part of PTEN's function in 8B). To further test the significance of the PTEN-p53 interaction on this activation, we performed the ChIP assay by co-transfectcontrolling tumor formation. The fact that naturally occurring mutations in the PTEN phosphatase domain (such as PTENing PTEN with either WT p53 or p53-⌬C mutant that is defective in PTEN interaction ( Figure 6B ). Similar to their effects on the C124S and PTEN-G129E mutants) are tumor causing indicates that the effects of PTEN's phosphatase-independent activity in endogenous p53, WT PTEN and PTEN-CS were able to increase the DNA binding activity of transfected p53 to the p21 promoter tumorigenesis may be more tissue specific or associated with a more aggressive phenotype upon loss of PTEN function. Howby 2.5-fold ( Figure 8C ). In contrast, neither WT PTEN nor PTEN-CS had any significant effect on the binding activity of ever, our data argue strongly that phosphatase-independent mechanisms are important parts of PTEN's biological functions. p53-⌬C ( Figure 8C ). These data suggest that PTEN regulates Notably, some recent studies suggest that activation of AKT p53 transcriptional activity, at least in part, by modulating its alone, such as overexpression of a constitutively activated form DNA binding activity. This modulation depends on the physical of AKT in transgenic mice, cannot account for all of the phenointeraction of PTEN and p53.
types related to PTEN loss (Ackler et al., 2002; Malstrom et al., 2001; Schwertfeger et al., 2001) . In Drosophila, phenotypes Discussion caused by dPTEN mutation are not completely covered by Dp110 or insulin-signaling mutants (Goberdhan et al., 1999) , A major portion of the PTEN literature focuses on the function of PTEN as a lipid phosphatase, and its antagonism of the suggesting PTEN may have a broader role than only antagonizing PIP3. Similarly, mutating the putative PIP2 motif in the PI3 kinase pathway. AKT phosphorylation/activation is generally regarded as the hallmark for PTEN mutation. In this study, we N-terminal region of PTEN led to loss of PTEN membrane association and failure to rescue the PTEN null phenotype in a define a novel role of PTEN as a tumor suppressor: PTEN con- Several important issues raised by the current study are DNA complex migration significantly ( Figure 8A ). The PTENstimulated p53-DNA complex could be supershifted by the addiworth further investigation. First, we have defined the C2 domain as a critical region involved in PTEN/p53 association and tion of anti-p53 antibody but not by the addition of anti-PTEN antibody, suggesting that PTEN may not be a part of the p53-PTEN-controlled p53 function. However, since a PTEN mutant that lacks the PTEN-C2 domain is unstable (Maehama et al., DNA complex (data not shown). Similar results were also reported with other proteins, such as c-Abl (Nie et al., 2000) and 2001; Simpson and Parsons, 2001) , we cannot rule out that other regions of the PTEN molecule may contribute to PTEN/p53
Ref-1 (Jayaraman et al., 1997b) , which interact with the C terminus of p53 and enhance p53 DNA binding. Two explanations complex formation. Second, it would be interesting to provide a mechanistic explanation as to why we cannot observe the may account for this result: first, PTEN may dissociate from the p53-DNA complex during the electrophoresis; second, PTEN PTEN/p53/MDM2 triple complex in vivo ( Figure 5A ) or MDM2 competing with PTEN in forming complex with p53 in vitro (see may induce a conformational change of latent p53 and dissociate from p53 once bound to DNA. Nevertheless, the ability Supplemental Figure S2 on Cancer Cell website). We hypothesize that the association of PTEN with the C-terminal negativeof PTEN to interact with p53 correlates well with its ability to enhances p53 DNA binding in vitro ( Figure 8A ) and in vivo (Figregulatory of tumor formation are significantly reduced in these animals.
To evaluate the role of PI3 kinase pathway in PTEN controlled p53 protein
These compound heterozygous mice, together with the one levels, cells were pre-treated with 50 nM wortmannin for 10 min and then we have generated in this study, also provide opportunities to proceeded to half-life study in the presence of wortmannin as described investigate the interplay between different signaling pathways above.
in tumor initiation, progression, and metastasis. Taken together, our study provides both genetic and bio- Laboratories), and AEC (3-amino-9-ethylcarbazole) substrate (BioGenex) were used for detection according to the recommended protocol.
Experimental procedures
Transcriptional activation assay Immortalization of MEF cells
The transcriptional activity of p53 was measured using pRGCE4Luc which Primary MEF cells were harvested from embryonic day 14 embryos with contains one copy of the RGC p53 binding site cloned upstream of the indicated genotype. Independent immortalized MEF lines were established adenovirus E4 TATA box and luciferase gene. Cells were lysed 24 hr post using the 3T9 protocol (Kamijo et al., 1997) . To derive Pten ⌬loxp/⌬loxp (⌬/⌬) cells, transfection in passive lysis buffer in accordance with the Dual-Glo Luciferimmortalized Pten loxp/loxp (L/L) cells, which were positive for Pten and p53 ase Assay System (Promega). Samples were normalized using Renilla Lucifexpressions, were transiently transfected with pTurbo-Cre (ES Cell Center, erase. Cells treated with LMB (10 M) were lysed 12 hr post LMB addition. Washington University, St Louis, Missouri) using Effectene transfection reagent (Qiagen) following recommended protocols. Individual colonies were Electrophoretic mobility shift assay (EMSA) expanded and tested for Pten deletion by both PCR and Western blot EMSA was carried out as described (Nie et al., 2000) . Briefly, the RGC p53 analysis (Lesche et al., 2002) , and approximately 30% of these clones had binding site probe (5Ј-AGCTTGCCTCGAGCTTGCCTGGACTTGCCTGGT the exon 5 of the Pten gene deleted.
CGACGC-3Ј) was 32 P-labeled with the Klenow fragment. Binding reactions contained 200 cpm of 32 P-labeled probe, 75 ng of wild-type p53, or 10 ng Cell culture and transfection of p53⌬C (⌬363), in the presence of 50 or 100 ng of GST-PTEN, GST-MEF and SAOS2 cells were cultured in Dulbecco's modified Eagle's medium PTEN-C, GST-PTEN-CT, GST, or GST-c-Abl, in a total volume of 12.5 l of (DMEM Gibco) supplemented with 10% fetal calf serum (FCS Hyclone), 100 reaction buffer (60 mM KCl, 12% glycerol, 5 mM MgCl 2 , 1 mM EDTA, 1 g U/ml penicillin and streptomycin (Gibco). To reintroduce PTEN-WT, CS, and BSA, 0.1 g poly [d(GC)]). Reactions were incubated at 30ЊC for 30 min, GR mutants, or PTEN-C2 domain into Pten ⌬/⌬ cells, the above plasmids were and then analyzed on a 5% polyacrylamide gel containing 0.5 ϫ TBE (0.045 cotransfected with a CMV-EGFP vector. GFP-positive cells were then FACS mM Tris-borate, 0.045 mM sodium borate, 0.001 mM EDTA [pH 8.0]). DNAsorted and analyzed as described. U2OS cells were cultured in McMoy's protein complexes were visualized with a PhosphorImager using Adobe 5A supplemented with 10% FCS. Cell transfection was performed using Photoshop software. lipofectAMINE (Invitrogen) or calcium phosphate method. Cells were lysed 28 hr post transfection for protein and luciferase activity measurements.
GST pulldown assay The p53 N-terminal and C-terminal deletion mutants were synthesized acWestern blot analysis and immunoprecipitation Whole-cell extract was prepared by lysing the cells in a buffer containing 50 cording to conditions recommended by the manufacturer (Promega). The mRNAs were translated in vitro for 1.5 hr at 30ЊC in rabbit reticulocyte mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, 0.25% Na Deoxycholate, 1 mM DTT, 2 g/ml aprotinin, and 2 g/ml leupeptin. Brain tissue was dislysate in the presence of 35 S-methionine. Bacterially expressed GST-PTEN or PTEN-CS was incubated for 60 min with Glutathione-Sepharose (Pharrupted using a Sonic Dismembrator in buffer containing 50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.5% NP-40, 0.25% Na Deoxycholate, 1 mM DTT, 2 macia) in lysis buffer (20 mM Tris-borate [pH 8.0], 150 mM NaCl, 1% Triton X-100, 10% Glycerol, 2 mM EDTA, 2 mM DTT, 2 g/ml Aproptinin, 2 g/ml g/ml aprotinin, and 2 g/ml leupeptin. Cell lysates from each transfection were subjected to SDS-PAGE followed by Western blot analysis using antiLeupeptin. 0.5 mM PMSF). Beads were then incubated for 60 min with the 35 S-methionine labeled p53 mutants in incubation buffer (20 mM HEPES [pH p53 (DO.1, Pab-240, Santa Cruz, FL-393-G, Santa Cruz), PTEN (9552, Cell Signaling Technologies), MDM2 (SMp14, Santa Cruz, Ab-2, Oncogene Re-7.4], 150 mM KCl, 0.1% Triton X-100, 10% Glycerol, 0.1 mg/ml BSA, 5 mM EDTA, 5 mM DTT, 4 g/ml Aproptinin, 4 g/ml Leupeptin, 1 mM PMSF) search Products), or Vinculin (VIN-11-5, Sigma) or Actin (A 4700, Sigma) antibodies, respectively.
with constant mixing. After incubation, the beads were washed three times
